Brainstorm Cell Therapeutics (NASDAQ:BCLI), trading on NASDAQ under the symbol BCLI, is a biotechnology company focused on the development and commercialization of innovative cell therapies for neurodegenerative diseases. Its lead investigational product, NurOwn, uses autologous mesenchymal stem cells (MSCs) engineered to secrete high levels of neurotrophic factors, aiming to protect and repair damaged neurons. The company’s proprietary platform seeks to address conditions with significant unmet medical needs, including amyotrophic lateral sclerosis (ALS), multiple sclerosis, Parkinson’s disease and Alzheimer’s disease.
The NurOwn process involves harvesting a patient’s own MSCs, expanding and differentiating the cells in a controlled laboratory setting, and then administering them back to the patient via intrathecal or intravenous infusion. Brainstorm has completed multiple clinical trials for ALS in the United States and is preparing for potential regulatory submissions. Preclinical research is under way to explore applications in additional neurological disorders, highlighting the platform’s versatility across a range of degenerative conditions.
Founded in 2000 and originally incorporated in Israel, Brainstorm Cell Therapeutics maintains research and manufacturing facilities in Ra’anana, Israel, along with a corporate office in New York. The company has built a global network of clinical collaborators and strategic partners to support its trials and future commercialization efforts. Brainstorm’s production capabilities adhere to Good Manufacturing Practice (GMP) standards, ensuring consistent quality and scalability of its cell therapy products.
Brainstorm is led by a management team of industry veterans with deep expertise in biotechnology, clinical development and regulatory affairs. The company’s scientific advisory board includes leading neurologists and stem cell researchers who guide its R&D strategy. By leveraging its cell therapy platform and fostering collaborative partnerships, Brainstorm Cell Therapeutics aims to bring new treatment options to patients affected by devastating neurodegenerative diseases.
